{"Title":"Zai Lab Ltd.","Industry":"PHARMACEUTICAL PREPARATIONS","Employees":"50","Founded":"","Address":"","Phone":"+86 21 6163 2588","Web_address":"http://www.zailaboratory.com","Market_cup":"$887.5mil","Revenues":"$0 mil (last 12 months)","Net_income":"$-50.1 mil (last 12 months)","Symbol":"ZLAB","Exchange":"NASDAQ","Shares":"8.3","Price_range":"$18.00 - $18.00","Est_volume":"$150.0 mil","Manager":"J.P. Morgan/ Citigroup/ Leerink Partners","CO_managers":"-","Exp_to_trade":"9/20/2017","Status":"","Quiet_period":"Available only to Subscribers","Lock_up_period":"Available only to Subscribers","Scoop_rate":"Available only to Subscribers","Rating_change":"Available only to Subscribers","Business":"We are an innovative biopharmaceutical company based in Shanghai focusing on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. We believe there exists a significant opportunity to build an organization that not only addresses such unmet needs but leverages underutilized resources in China to foster innovation."}